RNLX Renalytix: Nilai Akuntansi saben Saham

Renalytix Plc (RNLX) bases its development on the implementation of AI diagnostics in nephrology to reduce medical costs, while delegating test production and IT biomarker analysis to external contractors. The book value per share under Russian accounting standards reflects the equity trend, where the parameter value equals -0.05. Business stability is supported by low geopolitical risks and the free movement of products between Britain and the US.

Logistics disruption risks and sanction-related sales restrictions for Renalytix Plc (RNLX) diagnostic systems are directly reflected in the price action of the book value per ordinary share. This indicator determines the actual remaining net assets per share, calculated as the difference between total assets and liabilities, allowing investors to assess the company's real tangible value regardless of management's ambitious strategies.